Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

This study focuses on the natural history of relapsed multiple myeloma that is refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). ​ The study included 543 patients diagnosed between 2006 and 2014 who had received at least three prior lines of therapy, were refractory to both an IMiD and a PI, and had been exposed to an alkylating agent. ​ The median age at the time patients met the inclusion criteria was 62 years, with a range of 31-87 years. ​ The median overall survival (OS) from the time patients met the inclusion criteria was 13 months. ​ The study provides a benchmark for comparison of new therapies being evaluated for relapsed multiple myeloma that is refractory to a PI and an IMiD. ​

Important Points:

1. The study included 543 patients diagnosed between 2006 and 2014. ​
2. Patients had received at least three prior lines of therapy. ​
3. Patients were refractory to both an IMiD and a PI. ​​
4. Patients had been exposed to an alkylating agent. ​​
5. The median age at the time patients met the inclusion criteria was 62 years. ​
6. The median overall survival (OS) from the time patients met the inclusion criteria was 13 months. ​
7. The study provides a benchmark for comparison of new therapies for relapsed multiple myeloma refractory to a PI and an IMiD. ​

Authors:

Shaji Kumar, Meletios A Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, Jens Hillengass, Xavier Leleu, Meral Beksac, Melissa Alsina, Albert Oriol, Michele Cavo, Enrique M. Ocio, Maria Victoria Mateos, Elizabeth K. O’Donnell, Ravi Vij, Henk M. Lokhorst, Niels W.C.J. van de Donk, Chang-Ki Min, Tomer Mark, Ingemar Turesson, Markus Hansson, Heinz Ludwig, Sundar Jagannath, Michel Delforge, Charalampia Kyriakou, Parameswaran Hari, Ulf-Henrik Mellqvist, Saad Z Usmani, Dominik Dytfeld, Ashraf Z Badros, Philippe Moreau, Kihyun Kim, Paula Rodriguez Otero, Jae Hoon Lee, Chaim Shustik, Daniel Waller, Wee Joo Chng, Shuji Ozaki, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, Laura Rosinol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim and Brian G.M. Durie

Citation:

Leukemia advance online publication, 16 June 2017; doi:10.1038/leu.2017.138